Betta Pharmaceuticals files for HKEX listing; three first-in-class domestic targeted drugs commercialized, profitable for many consecutive years

NewTimeSpace News: On 28 August 2026, Betta Pharmaceuticals Co., Ltd. filed a listing application with HKEX. The Company is a major player in China's innovative drug R&D industry, having successfully transformed from a biotech company focused on drug discovery and development into a biopharmaceutical company operating across the full industry chain at the commercialization stage, with an operation platform driven by the coordinated "four engines" of independent R&D, market expansion, strategic cooperation and ecosystem building; the Company has been profitable for many consecutive years since its first product was launched in 2011.

According to the announcement, among the Company's commercialized drugs, icotinib (Conmana/Kaima'na, an EGFR TKI), ensartinib (Ensacove/Beima'na, an ALK TKI) and vorolanib (Fumeina, a VEGFR/PDGFR inhibitor) are each the first domestic drug of their respective class to be approved in China or to enter the global market for their targeted indications.

The Company has built a comprehensive drug pipeline covering key lung cancer targets, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), establishing a favorable position in innovative targeted lung cancer therapy, while also venturing into promising therapeutic areas including breast cancer, renal cancer, hematological diseases and ophthalmology; the Company remains committed to developing Class 1 innovative drugs designated by the NMPA, with a pipeline of more than ten clinical programs at various stages.

Through a portfolio strategy combining continuous value creation from commercialized products, global development of core pipeline assets and the steady advancement of next-generation candidates, the Company aims to build a sustainable innovation engine and deliver life-changing therapies to patients worldwide.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.